Abstract:AbstractHistone deacetylase inhibitors (HDACI) are promising antitumor agents. Although transcriptional deregulation is thought to be the main mechanism underlying their therapeutic effects, the exact mechanism and targets by which HDACIs achieve their antitumor effects remain poorly understood. It is not known whether any of the HDAC members support robust tumor growth. In this report, we show that HDAC6, a cytoplasmic-localized and cytoskeleton-associated deacetylase, is required for efficient oncogenic transformation and tumor formation. We found that HDAC6 expression is induced upon oncogenic Ras transformation. Fibroblasts deficient in HDAC6 are more resistant to both oncogenic Ras and ErbB2-dependent transformation, indicating a critical role for HDAC6 in oncogene-induced transformation. Supporting this hypothesis, inactivation of HDAC6 in several cancer cell lines reduces anchorage-independent growth and the ability to form tumors in mice. The loss of anchorage-independent growth is associated with increased anoikis and defects in AKT and extracellular signal-regulated kinase activation upon loss of adhesion. Lastly, HDAC6-null mice are more resistant to chemical carcinogen-induced skin tumors. Our results provide the first experimental evidence that a specific HDAC member is required for efficient oncogenic transformation and indicate that HDAC6 is an important component underlying the antitumor effects of HDACIs. [Cancer Res 2008;68(18):7561–9]

Hdac6: Physiological Function And Its Selective Inhibitors For Cancer Treatment

Histone deacetylase 6 in cancer

Structure, Functions and Selective Inhibitors of HDAC6

Recent development of selective inhibitors targeting the HDAC6 as anti-cancer drugs: Structure, function and design

Recent Development of Novel HDAC6 Isoform-Selective Inhibitors.

Curriculum vitae of HDAC6 in solid tumors

[Histone Deacetylase 6: Structure, Functions and Development of Selective Inhibitors].

HDAC6 mediates tumorigenesis during mitosis and the development of targeted deactivating agents

The Cytoplasmic Deacetylase HDAC6 is Required for Efficient Oncogenic Tumorigenesis

A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity

The Structure and Function of Histone Deacetylases: the Target for Anti-cancer Therapy

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy

HDAC7: a promising target in cancer

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

New Development of HDAC Inhibitors As Anti-Cancer Agents

The emerging roles of HDACs and their therapeutic implications in cancer

Effects of a novel HDAC6-selective inhibitor's radiosensitization on cancer cells

Targeting histone deacetylases for cancer therapy: Trends and challenges

Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.

Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors

Design, Synthesis, and Biological Evaluation of HDAC6 Inhibitors Based on Cap Modification Strategy.